[Skip to Navigation]
[Skip to Navigation Landing]
Observation
July 2017

Pembrolizumab-Induced Extensive Panniculitis and Nevus Regression: Two Novel Cutaneous Manifestations of the Post-immunotherapy Granulomatous Reactions Spectrum

Author Affiliations
  • 1Department of Dermatology, Hospital 12 de Octubre and Institute i+12, Medical School, Universidad Complutense, Madrid, Spain
  • 2Department of Pathology, Hospital 12 de Octubre and Institute i+12, Medical School, Universidad Complutense, Madrid, Spain
JAMA Dermatol. 2017;153(7):721-722. doi:10.1001/jamadermatol.2017.0581

Pembrolizumab, a humanized IgG4 PD-1 (programmed cell death 1) antagonist antibody, was recently approved for the treatment of advanced melanoma, non–small-cell lung cancer, and head and neck squamous cell carcinoma. As an immune checkpoint inhibitor (CPI), pembrolizumab has a unique toxic effects profile: CPI-induced sarcoidlike reactions are an emerging immune-related adverse event (irAE).1

×